| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.01. | Earth Science Tech, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.25 | Earth Science Tech, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.25 | Earth Science Tech reports Q2 results | 1 | Seeking Alpha | ||
| 12.11.25 | Earth Science Tech, Inc. Reports Strong Q2 Fiscal 2025 Results | 113 | GlobeNewswire (Europe) | MIAMI, FL, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ("ETST" or the "Company"), a strategic holding company focused on acquiring and scaling high-potential operating businesses... ► Artikel lesen | |
| EARTH SCIENCE TECH Aktie jetzt für 0€ handeln | |||||
| 12.11.25 | Earth Science Tech, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 14.10.25 | Earth Science Tech, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.08.25 | Earth Science Tech Increases Buyback Authorization To $10 Mln, Extends Plan By Two Years | 1 | RTTNews | ||
| 20.08.25 | Earth Science Tech expands share buyback to $10M, extends program through 2027 | 1 | Seeking Alpha | ||
| 20.08.25 | Earth Science Tech boosts share repurchase program to $10 million | 1 | Investing.com | ||
| 20.08.25 | Earth Science Tech, Inc. Boosts Share Repurchase Program to $10 Million and Extends Authorization Through 2027 | 5 | GlobeNewswire (USA) | ||
| 19.08.25 | Earth Science Tech, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 19.08.25 | Earth Science Tech board approves reduction of authorized common stock | 1 | Seeking Alpha | ||
| 19.08.25 | Earth Science Tech, Inc. Board of Directors Approves Reduction of Authorized Common Stock | 212 | GlobeNewswire (Europe) | Miami, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ("ETST" or the "Company"), a strategic holding company focused on acquiring and scaling high-potential businesses... ► Artikel lesen | |
| 11.08.25 | Earth Science Tech reports Q1 results | 1 | Seeking Alpha | ||
| 08.08.25 | Earth Science Tech, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.08.25 | Earth Science Tech, Inc. Reports 61% Asset Growth to $7.69 Million and $8.7 Million in First Quarter Revenue Following Foundational Quarter of Strategic Acquisitions | 152 | GlobeNewswire (Europe) | MIAMI, FL, Aug. 08, 2025 (GLOBE NEWSWIRE) -- MIAMI, FL - August 8, 2025 - Earth Science Tech, Inc. (OTC: ETST) ("ETST" or the "Company"), a strategic holding company focused on acquiring and scaling... ► Artikel lesen | |
| 27.06.25 | Earth Science Tech, Inc. Reports Fiscal Year-End Results for March 31, 2025, with Revenue Exceeding $33.1 Million and Net Profit of $3.2 Million | 170 | GlobeNewswire (Europe) | Miami, FL, June 26, 2025 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ("ETST" or "Company"), a strategic holding company, focused on value creation through the acquisition, operational... ► Artikel lesen | |
| 06.05.25 | Earth Science Tech, Inc. Annual Shareholder Letter FY Ending 03/31/2025 | 156 | GlobeNewswire (Europe) | Miami, FL, May 06, 2025 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) ("ETST" or "Company"), a strategic holding company, focused on value creation through the acquisition, operational... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 39,595 | -0,29 % | DAX: Nächster Angriff auf die 25.000 Punkte? Siemens, Bayer, Redcare und Nordex im Blickpunkt | Der DAX dürfte am Mittwoch weiter mit dem Sprung über die 25.000-Punkte-Marke liebäugeln. Der Broker IG taxierte den deutschen Leitindex zwei Stunden vor dem Auftakt 0,25 Prozent im Plus auf 24.955... ► Artikel lesen | |
| NOVO NORDISK | 51,64 | +0,43 % | Novo Nordisk: Aktie haussiert weiter | Der Start in das neue Börsenjahr 2026 ist der Aktie von Novo Nordisk absolut geglückt. Im heutigen Handel legt die Aktie des dänischen Pharmariesen erneut kräftig zu. Aktuell beläuft sich das Plus des... ► Artikel lesen | |
| HARROW | 47,840 | 0,00 % | Harrow, Inc.: Harrow Health, Inc. Announces Closing of Acquisition of Melt Pharmaceuticals | NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,510 | 0,00 % | Faruqi & Faruqi LLP: INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics | Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their OptionsIf... ► Artikel lesen | |
| MERCK KGAA | 129,85 | -1,07 % | BARCLAYS stuft MERCK KGAA auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Merck KGaA von 120 auf 130 Euro angehoben und die Einstufung auf "Equal Weight" belassen. Für den Pharma- und Spezialchemiekonzern... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 88,12 | +1,58 % | Bright Minds Biosciences Announces Closing of US$175 Million Public Offering | NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 15,470 | 0,00 % | Eton Pharmaceuticals, Inc. - 8-K, Current Report | ||
| LB PHARMACEUTICALS | 19,030 | -8,20 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture | NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for... ► Artikel lesen | |
| LIPOCINE | 9,030 | 0,00 % | Lipocine Inc.: Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) | Company on track to report topline results early in the second quarter of 2026
Second planned Data and Safety Monitoring Board (DSMB) meeting evaluated all available... ► Artikel lesen | |
| MILESTONE PHARMACEUTICALS | 1,960 | -3,92 % | Milestone Pharmaceuticals Inc. - 8-K, Current Report | ||
| JAGUAR HEALTH | 0,840 | 0,00 % | Jaguar Health, Inc.: Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million | $18M upfront payment to Jaguar ($16M upon deal closing and $2M upon completion of post-closing conditions)Up to additional $20M in milestone and other future paymentsFuture Pak becomes exclusive U.S.... ► Artikel lesen | |
| MERCK & CO | 93,50 | -0,21 % | Neue Gerüchte! Merck & Co wirft Auge auf AKTIONÄR-Tipp Revolution Medicines | Der US-Pharmariese Merck & Co bereitet offenbar den nächsten großen Coup vor. Laut Insidern befindet sich der Konzern in fortgeschrittenen Gesprächen über den Kauf des Krebsspezialisten Revolution Medicines.... ► Artikel lesen | |
| JOURNEY MEDICAL | 7,740 | +6,46 % | Journey Medical (DERM) Publishes Positive Emrosi Phase 1 Microbiome Data | ||
| NEWRON PHARMACEUTICALS | 30,150 | -8,64 % | EQS-News: Newron Pharmaceuticals S.p.A.: Newron erweitert IP-Portfolio mit neuem EU-Stoffpatent für Evenamide | EQS-News: Newron Pharmaceuticals S.p.A.
/ Schlagwort(e): Patent
Newron erweitert IP-Portfolio mit neuem EU-Stoffpatent für Evenamide
06.01.2026 / 07:00 CET/CEST
Für... ► Artikel lesen | |
| PFIZER | 21,670 | +0,05 % | UBS stuft PFIZER INC auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Pfizer mit "Neutral" und einem Kursziel von 25 US-Dollar in die Bewertung aufgenommen. Hinsichtlich der Umsatzentwicklung des US-Pharmakonzerns... ► Artikel lesen |